GlassScriptPhysician profile
Ziad U Khan
NPI 1528386687
$40,277.57
in general payments reported to CMS, 2019-2025
77 companies · $5,522 in 2025
The $5,522 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,844 · 2020: $2,958 · 2021: $3,442 · 2022: $4,491 · 2023: $4,823 · 2024: $15K · 2025: $5,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,500 · Travel and Lodging: $1,677 · Education: $48.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,318.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,500.00 |
| Travel and Lodging | $1,676.62 |
| Education | $48.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11,461.39 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $2,332.68 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $2,264.11 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,989.07 | 2019-2025 | Opdivo, Reblozyl |
| Janssen Biotech, INC. | $1,964.39 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Astrazeneca Pharmaceuticals LP | $1,579.31 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Celgene Corporation | $1,310.81 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| Genentech USA, INC. | $1,278.40 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Genzyme Corporation | $966.56 | 2019-2025 | |
| Amgen INC. | $897.27 | 2019-2023 | Kyprolis |
| Incyte Corporation | $877.12 | 2019-2025 | Jakafi, Monjuvi |
| Astellas Pharma US INC | $815.47 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Eisai INC. | $667.50 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $601.94 | 2021-2025 | Fotivda |
| Lilly USA, LLC | $589.47 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.